| Similar Articles |
|---|
 |
The Motley Fool
July 5, 2005
Bill Mann |
This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it.   |
The Motley Fool
April 27, 2005
Charly Travers |
Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders. |
The Motley Fool
June 21, 2005
Charly Travers |
A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire. |
The Motley Fool
July 26, 2005
Gardner & Mann |
For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals. |
The Motley Fool
January 26, 2005
John Bluis |
Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease. |
The Motley Fool
February 24, 2005
Charly Travers |
Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
May 10, 2005 |
Fair Value, Explained Don't confuse a stock's price with its fair value. |
The Motley Fool
May 1, 2006
Rich Duprey |
Searching for Profits in R&D: Part 1 Here's why treating R&D as an investment can lead you to some up-and-coming small caps worthy of your investment dollars. |
The Motley Fool
June 28, 2007
Anders Bylund |
Dueling Fools: NYSE Euronext Bull Rebuttal Investors, valuation is a fickle mistress. NYSE is expected to darn near double its earnings over the next year and to grow earnings per share at a compound rate of 28% over the next five years. |
Financial Advisor
April 2006
David DeVoe |
True Value Understanding what drives the value of your financial advisory firm will not only increase your payday when you sell, it will also increase the firm's profitability -- and consequently, your compensation -- each year you continue to own the business. |
The Motley Fool
August 20, 2007
Brian Lawler |
Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen... |
The Motley Fool
September 22, 2006
Stephen Ellis |
Is Finish Line Finished? A hedge fund believes the company can best serve shareholders by selling out. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
August 4, 2009
Matt Koppenheffer |
How Long Should You Ride This Rally? This rally in the market has been a great ride, but is it time to hop off? |
The Motley Fool
November 11, 2004
Marko Djuranovic |
Take a Shot on CancerVax? The company still isn't profitable, but big gains may be on the horizon for this biotech. |
Investment Advisor
March 1, 2011
Jeff Joseph |
Putting a Price on a Promise How do private venture investors assign a value to a new company at the startup stage? |
The Motley Fool
October 7, 2004
Seth Jayson |
Painless? My Assets Another warning from dental tech firm Biolase Technology sends the stock down. |
Inc.
July 1, 2003
Randall Lane |
What's Your Company Worth Now? Knowledge is power, and knowledge of your company's value is the ultimate power tool. Here's what you need to calculate your own magic number. |
The Motley Fool
August 9, 2005
Seth Jayson |
The Investor's Frame of Mind Curiosity is the successful investor's prime attribute. |
